Piramal Pharma Ltd.
NSE: PPLPHARMA | BSE: 543635
₹176.08
₹-0.27
(-0.15%)
As on 21-May-2026IST
Market cap
₹23,381 Cr
Revenue (TTM)
₹8,869 Cr
P/E Ratio
--
P/B Ratio
2.9
Div. Yield
0 %
Quality Score
1/10
Growth Score
3/10
Valuation Score
2/10
Momentum Score
3/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹-326 Cr
-
ROE
1.1 %
-
ROCE
6.6 %
-
Industry P/E
44.31
-
EV/EBITDA
24.4
-
Debt to Equity
0.5
-
Book Value
₹61.4
-
EPS
₹-2.6
-
Face value
10
-
Shares outstanding
1,329,248,130
5 Years Aggregate
CFO
₹3,744.73 Cr
EBITDA
₹5,594.24 Cr
Net Profit
₹1,133.48 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Piramal Pharma
| 2.2 | 18.3 | 9.7 | -14.4 | 35.1 | -- | -- |
|
BSE Healthcare
| 10.2 | 10.3 | 11.1 | 13.4 | 28.1 | 14.5 | 12.1 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
Piramal Pharma
| -33.3 | 92.2 | 24.0 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Piramal Pharma
|
176.1 | 23,381.5 | 8,869.1 | -383.1 | 1.0 | -4.2 | -- | 2.9 |
| 3,000.4 | 24,554.0 | 1,339.4 | 356.4 | 33.2 | 23.2 | 68.9 | 14.8 | |
| 419.9 | 16,087.0 | 2,268.6 | 150.1 | 10.6 | 5.4 | 89.8 | 4.1 | |
| 764.2 | 18,926.7 | 5,365.6 | 595.0 | 16.6 | 13.3 | 31.8 | 3.7 | |
| 1,011.7 | 16,107.3 | 7,918.4 | 429.9 | 10.7 | 7.2 | 37.2 | 2.4 | |
| 1,174.3 | 21,003.3 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 13.5 | 2.4 | |
| 1,861.8 | 21,346.5 | 1,421.6 | -73.8 | 1.8 | -1.1 | -- | 3.7 | |
| 969.1 | 15,995.8 | 1,284.3 | 134.4 | -- | 30.7 | 119 | 13.1 | |
| 470.2 | 18,982.5 | 3,738.7 | 316.7 | 12.5 | 7.5 | 59.9 | 3.9 | |
| 1,599.8 | 26,016.6 | 3,373.0 | 199.0 | 12.6 | 5.9 | 122.1 | 5.3 |
Shareholding Pattern
View DetailsNews & Analysis
All News
About Piramal Pharma
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing... facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; offers inhalation anesthetics, intrathecal therapy, injectable pain and anesthesia drugs, and other generic and specialty products; and analgesics, skin care, vitamin/mineral supplement, kids' wellness, digestives, women's health, and hygiene, as well as adult incontinence. The company was incorporated in 2020 and is based in Mumbai, India. Read more
-
Incorporated
2020
-
Chairman
Nandini Piramal
-
Managing Director
--
-
Headquarters
Mumbai, Maharashtra
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
Quarterly Updates
Annual Reports
Announcements
View AnnouncementsNo News & Announcements are available.
FAQs for Piramal Pharma
What is the current share price of Piramal Pharma Ltd Today?
The share price of Piramal Pharma Ltd is ₹176.08 (NSE) and ₹175.90 (BSE) as of 21-May-2026 IST. Piramal Pharma Ltd has given a return of 35.14% in the last 3 years.
What is the current PB & PE ratio of Piramal Pharma Ltd?
Since, TTM earnings of Piramal Pharma Ltd is negative, P/E ratio is not available.
The P/B ratio of Piramal Pharma Ltd is 2.86 times as on 21-May-2026, a 26 discount to its peers’ median range of 3.89 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
326.26
|
3.69
|
|
2024
|
956.95
|
2.16
|
|
2023
|
0.00
|
1.21
|
|
2022
|
0.00
|
0.00
|
|
2021
|
0.00
|
0.00
|
What is the 52 Week High and Low of Piramal Pharma Ltd?
The 52-week high and low of Piramal Pharma Ltd are Rs 220.85 and Rs 132.30 as of 21-May-2026.
What is the market cap of Piramal Pharma Ltd?
Piramal Pharma Ltd has a market capitalisation of ₹ 23,381 Cr as on 21-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Piramal Pharma Ltd?
Before investing in Piramal Pharma Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.